Forte Pharma, Reig Jofre’s nutritional supplements line, enters in Hong Kong and Macao
This operation is part of Reig Jofre's internationalization plan, by which 60% of company sales are now made outside Spain, with a target of 70% in 2019.
Forte Pharma, Reig Jofre’s nutritional supplements line, has recently entered Hong Kong and Macao through RS Lifestyle, a local partner, leader in the distribution of consumer products.
Watson’s drugstores, with more than 200 stores all around Hong Kong and Macao, has been the entry door for Forte Pharma in these markets, where the company has launched Vitality 4 from the energy range; and Turboslim Calorie Trapper, Turboslim Drink Peach tea and Turboslim Fat Redux 900 mg from slimming range.
Vitality 4, Turboslim Calorie Trapper, Turboslim Drink Peach tea and Turboslim Fat Redux 900 mg are among the top five products in Forte Pharma sales, and the first three with more than 10 years of recognized market position in its category. Turboslim Fat Redux was launched in 2014.
Following its integration in the pharmaceutical company Reig Jofre, Forte Pharma designed an expansion plan into new markets through agreements with local distributors. As a result of this strategy, in 2015 Forte Pharma initiated contacts in a dozen markets in Europe and Asia, which allowed as first achievement to formalize the entry into Hong Kong and Macao in the first months of 2016.
This operation is part of Reig Jofre's internationalization plan, by which 60% of company sales are now made outside Spain, with a target of 70% in 2019.
At present, marketing of Forte Pharma products is done mostly in Europe through its own sales network. In the coming years the company estimates a potential significant growth in markets where Forte Pharma is not yet present.
Forté Pharma products are organized into four ranges: slimming (54% of its total sales), energy (18%), beauty (17%) and health (11%). Revenues from the area of nutritional supplements and consumer healthcare, to which Forte Pharma belongs, amounted to 35 million euros in 2015, 22% of Reig Jofre total turnover, with a growth of 3% compared to 2014.
François Gaydier, Forte Pharma’s General Manager, said: "We hope that the entry into Hong Kong will help us to lay a solid foundation for further growth in the future via distribution agreements, since our goal is to launch other products in this market in the short term and expand our brand in other Asian countries."
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.